230 related articles for article (PubMed ID: 14735202)
1. SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.
Astuti D; Da Silva NF; Dallol A; Gentle D; Martinsson T; Kogner P; Grundy R; Kishida T; Yao M; Latif F; Maher ER
Br J Cancer; 2004 Jan; 90(2):515-21. PubMed ID: 14735202
[TBL] [Abstract][Full Text] [Related]
2. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.
Morris MR; Hesson LB; Wagner KJ; Morgan NV; Astuti D; Lees RD; Cooper WN; Lee J; Gentle D; Macdonald F; Kishida T; Grundy R; Yao M; Latif F; Maher ER
Oncogene; 2003 Oct; 22(43):6794-801. PubMed ID: 14555992
[TBL] [Abstract][Full Text] [Related]
3. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.
Wagner KJ; Cooper WN; Grundy RG; Caldwell G; Jones C; Wadey RB; Morton D; Schofield PN; Reik W; Latif F; Maher ER
Oncogene; 2002 Oct; 21(47):7277-82. PubMed ID: 12370819
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
5. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
9. Correlations between histological characterizations and methylation statuses of tumour suppressor genes in Wilms' tumours.
Lai YC; Lu MY; Wang WC; Hou TC; Kuo CY
Int J Exp Pathol; 2022 Jun; 103(3):121-128. PubMed ID: 35436013
[TBL] [Abstract][Full Text] [Related]
10. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
[TBL] [Abstract][Full Text] [Related]
11. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
[TBL] [Abstract][Full Text] [Related]
12. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
13. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
[TBL] [Abstract][Full Text] [Related]
14. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers.
Dickinson RE; Dallol A; Bieche I; Krex D; Morton D; Maher ER; Latif F
Br J Cancer; 2004 Dec; 91(12):2071-8. PubMed ID: 15534609
[TBL] [Abstract][Full Text] [Related]
17. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
18. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
19. Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma.
Brodeur GM
Cancer Surv; 1995; 25():67-99. PubMed ID: 8718513
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.
Wong IH; Chan J; Wong J; Tam PK
Clin Cancer Res; 2004 Feb; 10(3):994-1002. PubMed ID: 14871978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
